Abstract: The invention relates to post-transfusional non-A non-B hepatitis viral polypeptide, DNA sequences encoding such viral polypeptide, expression vectors containing such DNA sequences, and hosts transformed by such expression vectors. The invention also relates to the use of such polypeptides in diagnostic assays and vaccine formulations.

Abstract: Disclosed are compounds of the formula wherein R1 is hydrogen or an acyl group having 1 to 16 carbon atoms; R2 is a purine or pyrimidine base or an analogue or derivative thereof; Z is O, S, S?O or SO2; and pharmaceutically acceptable derivatives thereof. Also described are processes for and intermediates of use in their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds in the antiviral treatment of mammals.

Abstract: The invention relates to antibodies which bind to the CD23 (FC?RII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FC?RII) type II molecule characterized by an affinity constant equal to or greater than 1×109 Ka Mol?1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.

Abstract: The present invention relates to an improved analytical method and apparatus therefor, in particular to a method and apparatus for continuous titration in which at least one parameter of at least one compound in a test mixture may be monitored as the composition of the mixture is continuously varied. The method comprises the steps of continuously mixing at least two component fluid streams to form a test mixture stream and passing the test mixture stream through a spectrophotometric detection zone, with the volume to volume ratio of at least two of the component streams forming the test mixture stream continuously and linearly varied with time by alteration of the relative proportions of the component streams forming the test mixture, while the total volume of the test mixture stream remains constant.

Abstract: A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.

Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.

Abstract: Devices and methods are provided to facilitate the evaluation of the quality of a combinatorial library of compounds. One exemplary device comprises a holding plate having an array of apertures. A plurality of vials are removably held within the apertures. Each of the vials has an open top end. A seal member is disposed over the top ends of the vials, and a top plate is removably coupled to the holding plate to force the seal member against the top ends of the vials.

Abstract: The present invention relates to an improved analytical method and apparatus therefor, in particular to a method and apparatus for continuous titration in which at least one parameter of at least one compound in a text mixture may be monitored as the composition of the mixture is continuously varied.

Abstract: The invention provides a cloned polynucleotide having the function of a transcriptional regulatory sequence (trs) and comprising: (a) a polynucleotide fragment having at least 70% identity to the polynucleotide of SEQ ID NO.:2; (b) a polynucleotide which is complementary to the polynucleotide of (a); or (c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b).

Abstract: Elongated drug, especially salbutamol sulphate, and/or carrier particles, especially lactose, pharmaceutical compositions comprising the same, and use of the elongated particles in the manufacture of a medicament for the treatment of respiratory disease.

Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.

Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.

Abstract: A compound of formula (I) wherein R1 is phenyl substituted by one or more halogen atoms; R2 is —NH2; R3 is —NH2 or hydrogen; R4 is —CXNRaRb, —CXNH—(CH2)y—NRaRb; wherein X is ═O or ═S; y is an integer zero, 1 or 2; Ra and Rb, which may be the same or different, are selected from hydrogen and C1-4 alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocycle containing one or two nitrogen heteroatoms, which heterocycle can be further substituted with one or more C1-4 alkyl groups; and pharmaceutically acceptable derivatives thereof.

Abstract: Compounds of formula (I) 1

Abstract: According to a first aspect of the invention there is provided compounds of formula (I): wherein: R1 is hydroxy; O-acetyl; or a halo atom; R2 is hydroxy; O-acetyl; or a halo atom; R3 is hydrogen; a halo atom; azido; C2-6alkenyl; C2-6alkynyl; C6-14aryl C2-6alkenyl; C6-14arylC2-6alkynyl —NR8R9 (where R8 and R9 may be the same or different and are hydrogen, C1-8alkyl, cyanoC1-8alkyl, hydroxyC1-8alkyl, haloC1-8alkyl, C3-7cycloalkyl, C1-8alkylC3-7cycloalkyl, C2-6alkenyl, C3-7cycloalkylC1-8alkyl, C2-6alkynyl, C6-14aryl, C6-14arylC1-8alkyl, heterocycleC1-8alkyl, C1-8alkylcarbonyl, C6-14arylsulfonyl, C1-8alkysulfonyl, or R8R9 together with the N atom to which they are attached form a 3,4,5 or 6 membered heterocyclic ring); —OR10 (where R10 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl, C2-6alkenyl, C2-6alkynyl, C6-14aryl C2-6alkenyl or C6-14arylC2-6alkynyl); or —SR11 (where R11 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl).

Abstract: The subject invention concerns eryloside F, a novel disaccharide of the steroidal carboxylic acid penasterol. This compound can be isolated from an extract of the marine sponge Erylus formosus. The compound is a potent thrombin receptor antagonist and, furthermore, inhibits human platelet aggregation. Longer chain penasterol oligosaccharides were also isolated and characterized but these had weaker activity than eryloside F. The subject invention also concerns methods for inhibiting thrombin receptor activity and methods for inhibiting platelet aggregation through the administration of eryloside F, or a salt, derivative or analog thereof.

Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by ca

Abstract: A method of testing the purity or stability to degradation of a sample of lamotrigine or a pharmaceutical dosage form comprising lamotrigine comprises assaying the said sample for the presence of a compound selected from 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazine-5-(4H)-one (compound A) and N-[5-amino-6-(2,3-dichlorophenyl)-1,2,4-triazine-3-yl]-2,3-dichlorobenzamide (compound B). A process for producing compound B, which is novel, is also disclosed.

Abstract: Neuraminidase and galactose oxidase together are a vaccine adjuvant.

Abstract: The present invention provides a compound of formula (I) or a solvate thereof wherein: X is —O— or —NH—; Q is (—CH2—)p, (—CH═CH—)p, (—C≡C—)p where p is an integer of from 0 to 4; R1 is hydrogen or methyl; R2 and R3 independently represent O or S n is an integer of 1 to 50; and R is hydrogen or methyl. The present invention also provides pharmaceutical compositions and methods of treatment using the compounds of formula (I). The compounds of the present invention are useful for the prophylaxis and treatment of septic shock, inflammatory conditions and immune disorders.